| Bioactivity | MK6-83 is a new candidate agonist of TRPML1 with an improved efficacy and potency. MK6-83 has the potential for Mucolipidosis type IV study[1]. | ||||||||||||
| Invitro | MK6-83 2 ranging from 0.2 to 30 μM shows no signs of cytotoxicity[1].MK6-83 appears to be significantly more efficacious on fibroblast lysosomes isolated from R403C or V446L expressing cells than on those isolated from TRPML1-/- cells[1]. Cell Viability Assay[1]. Cell Line: | ||||||||||||
| Name | MK6-83 | ||||||||||||
| CAS | 1062271-24-2 | ||||||||||||
| Formula | C16H20N2O2S2 | ||||||||||||
| Molar Mass | 336.47 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Cheng-Chang Chen, et al. A Small Molecule Restores Function to TRPML1 Mutant Isoforms Responsible for Mucolipidosis Type IV. Nat Commun. 2014 Aug 14;5:4681. |
MK6-83
CAS: 1062271-24-2 F: C16H20N2O2S2 W: 336.47
MK6-83 is a new candidate agonist of TRPML1 with an improved efficacy and potency. MK6-83 has the potential for Mucolipi
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.